Europe

Mar 21, 2016
NICE's notion to charge the industry for its technology appraisals looks set to become reality, writes Leela Barham.
Mar 10, 2016
Elvis Pacelat asks why the prospect of harmonized content is so challenging, and what can pharma companies learn from other sectors about more optimal, modern ways of working and sharing data?
Mar 06, 2016
Pharmaceutical Executive
A new study spells out the many drug pricing problems in Europe just fine, but fails to address a central access issue.
Feb 25, 2016
As a European politician attacks abuses of the orphan drug scheme, an EU report extols its virtues. Reflector asks: in Europe, does the right hand know what the left hand is doing?
Feb 17, 2016
Following the consultation on the future of England's Cancer Drug Fund, Leela Barham reviews what the stakeholders are thinking.
Jan 27, 2016
It's an obvious question for every pharmaceutical executive — and the question no-one dares to answer: what happens if the UK leaves the EU?
Jan 04, 2016
Gülce Belgin and Donald Macarthur explore the options available for companies to meet the needs of the rare disease population in Turkey.
Nov 30, 2015
The Parliamentary Assembly of the Council of Europe is the latest to clamber aboard the well-filled bandwagon now rumbling and rattling across Europe in an increasingly noisy debate over drug prices. Reflector reports.
Nov 25, 2015
The much awaited consultation on a ‘new’ Cancer Drugs Fund (CDF) in England has finally emerged. Leela Barham reports.
native1_300x100
lorem ipsum